Xiamen Humanity Hospital
Kidney cancer treatment cost in China typically includes diagnostics like a CT of the chest, which runs from $300 to $600. Primary surgical interventions such as nephrectomy range between $14,500 and $26,500, while a nephrectomy with Da Vinci Robot costs $24,500 to $35,000. Total expenses depend on cancer stage and surgical technique, offering 50-70% savings compared to the US. Key medical hubs include Guangzhou, Shanghai, and Beijing.
Typical Kidney Cancer Treatment Costs in China
Bookimed Expert Insight: Late-stage patients find high value in specialized therapies beyond standard chemotherapy. Fuda Cancer Hospital provides over 10 types of minimally invasive options, including NanoKnife and cryosurgery. Dr. Niu Lizhi at Fuda has performed nearly 10,000 cryosurgeries with world-renowned results. For advanced cases, JCI-accredited facilities in Guangzhou provide multidisciplinary care that balances advanced technology with significant savings.
| China | Turkey | Austria | |
| Radiation therapy for kidney cancer | from $12,500 | from $6,500 | from $6,856 |
| Radiation therapy for colorectal cancer | from $11,500 | from $7,000 | from $12,000 |
| Proton-beam therapy | from $36,500 | from $70,000 | from $80,000 |
| Nephrectomy with Da Vinci Robot | from $24,500 | from $10,000 | from $16,000 |
| Nephrectomy | from $14,500 | from $10,000 | from $22,000 |
Performed nearly 10,000 cryosurgeries – Prof. Niu Lizhi leads Fuda Cancer Hospital and specializes in minimally invasive techniques for kidney cancer.
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.
Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.
Leading Chinese hospitals treat kidney cancer using robotic-assisted nephrectomy, cryosurgery, and targeted therapies. Specialized centers combine minimally invasive surgery with advanced ablation for small tumors. High-volume academic institutions utilize the da Vinci system for precise, nephron-sparing procedures. These methods aim to preserve healthy kidney tissue.
Bookimed Expert Insight: China is a global leader in cryosurgery for kidney cancer. Professor Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries. This procedure is often used for tumors smaller than 4 cm. It offers a safe alternative for elderly patients. The hospital is JCI-accredited and treats patients from over 100 countries. Specialist experience at this volume is rare in many other regions.
Patient Consensus: Patients note that robotic surgery allows for a quick recovery and usually avoids blood transfusions. Many emphasize the importance of using WeChat groups to find real-time tips for navigating large hospitals.
Major Chinese kidney cancer centers are safe and offer specialized care at international quality levels. Top-tier institutions like Fuda Cancer Hospital hold JCI accreditation. National data shows 5-year survival rates for renal cell carcinoma reaching 69.8%. These figures now closely track performance in high-income western nations.
Bookimed Expert Insight: While general survival rates are high, the true value in China lies in specialized cryosurgery and NanoKnife technology for advanced cases. Fuda Cancer Hospital treats over 30,000 international patients annually. This massive volume allows surgeons to maintain expertise in complex, minimally invasive techniques that may be less common elsewhere. For example, Dr. Niu Lizhi treats a vast age range from 4 to 94 years old. This suggests a high level of technical adaptability for high-risk patients.
Patient Consensus: Patients note that top-tier hospitals provide excellent technical outcomes and advanced surgical technology. They suggest hiring a translator to help manage side effects and clarify follow-up instructions during recovery.
Fuda Cancer Hospital in Guangzhou and Beijing United Family Hospital are among Chinas most experienced facilities for international kidney cancer patients. These JCI-accredited centers specialize in minimally invasive technologies. They offer advanced cryosurgery, NanoKnife therapy, and robotic nephrectomy for complex or late-stage cases.
Bookimed Expert Insight: While many seek robotic surgery, Chinas specific advantage in kidney cancer lies in non-surgical ablation. Fuda Cancer Hospital provides over 10 types of minimally invasive therapies. Dr. Niu Lizhi is a global authority in cryosurgery. This makes these clinics a primary choice for patients with tumors in difficult locations.
Patient Consensus: Patients often favor major cities like Beijing and Shanghai for metastatic cases. They note that English-speaking staff and JCI accreditation at private international hospitals ensure much smoother medical journeys.
Recovery after kidney cancer surgery in China typically requires 3 to 5 days of hospitalization. Minimally invasive procedures like cryoablation or NanoKnife often allow for discharge within 48 hours. Follow-up protocols include abdominal CT or MRI every 3 to 6 months during the first 2 years.
Bookimed Expert Insight: Clinical volume significantly impacts expertise in specialized treatments like cryosurgery. Professor Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries personally. This high procedural volume at JCI-accredited centers often leads to more refined recovery protocols for complex late-stage cases.
Patient Consensus: Patients note that while physical recovery from ablation is fast, adhering to the 6-week lifting restriction is vital to prevent internal bleeding. Many also suggest using translation apps to navigate medical documents, as getting English-language scan reports can be challenging.
Ideal candidates for minimally invasive ablation in China include patients with small kidney tumors under 4 cm (stage T1a). This approach suits individuals with high surgical risks due to age or heart disease. It specifically benefits those needing to preserve renal function or managing a solitary kidney.
Bookimed Expert Insight: While many overlook specialized oncology centers, Fuda Cancer Hospital in Guangzhou provides a distinct advantage with over 10,000 cryosurgeries performed. Professor Niu Lizhi has personally completed 500 NanoKnife procedures, which is a rare expertise level globally. Patients should prioritize these high-volume centers, as specialized experience with NanoKnife and cryoablation often leads to better preservation of healthy kidney tissue than generalized surgical departments.
Patient Consensus: Patients note that ablation offers a much faster recovery with minimal scarring compared to open surgery. Many emphasize that while it carries a slightly higher recurrence risk, the benefit of keeping 80% of kidney function makes it the preferred choice for early-stage cases.
Integrative oncology in China is a patient-centered field combining conventional medical treatments with evidence-informed complementary therapies. This integrated Chinese and Western medicine model uses technologies like the Da Vinci Robot or CyberKnife M6 alongside traditional practices to manage symptoms and improve quality of life.
Bookimed Expert Insight: Our data highlights that top Chinese centers often replace aggressive chemotherapy with over 10 types of minimally invasive therapies. For instance, Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries for advanced stages. These clinics often hold JCI accreditation, ensuring that traditional integrations meet rigorous international safety standards. Patients seeking this approach should prioritize hospitals with high international patient volumes, such as those serving 30,000+ people from 100 countries.
Patient Consensus: Patients note that combining partial nephrectomy with specific herbs helps strengthen their energy and may stabilize tumors before surgery. Many emphasize the importance of using monitored medical teams to ensure herbs do not interfere with standard kidney function.
Guangzhou, Beijing, and Shanghai are China's primary hubs for advanced kidney cancer treatment. These cities host JCI-accredited facilities specializing in minimally invasive oncology. International patients often access cryosurgery, NanoKnife ablation, and robotic-assisted nephrectomy. Specialized centers in these regions offer multidisciplinary care for complex renal cases.
Bookimed Expert Insight: Guangzhou stands out for specialized experience in late-stage renal cases. Dr. Niu Lizhi at Fuda Cancer Hospital has performed over 10,000 cryosurgeries. This high volume often allows for treating patients aged 4 to 94. While Shanghai and Beijing offer traditional excellence, Guangzhou's focus on non-invasive ablation makes it a focal point for those seeking alternatives to standard surgery.
Patient Consensus: Patients note that Shanghai and Beijing offer world-class urology technology. Many emphasize hiring a local translator or fixer to manage visa paperwork and post-operative care communication.
Kidney cancer treatment in China centres on surgical techniques and non-invasive ablation therapies. Specialists use robotic systems for precise tumour removal. They also offer cryosurgery for patients seeking alternatives to major surgery. Leading centres in Guangzhou and Xiamen provide care including immunotherapy and precision radiation.
Bookimed Expert Insight: China is a global leader in cryosurgery, especially for patients who cannot undergo traditional surgery. While many Western hospitals use cryotherapy sparingly, Professor Niu Lizhi at Fuda Cancer Hospital has completed almost 10,000 procedures. This high volume often leads to better outcomes when preserving kidney function is the primary goal.
Patient Consensus: Patients value the availability of non-surgical options like NanoKnife and cryotherapy in China. They often highlight the importance of arranging English-speaking support. They also suggest confirming how pathology reports will be shared with their GP back in Australia.
Robotic partial nephrectomy is widely available across China. Over 400 robotic platforms are now installed in major cities. Urological procedures account for 48% of all robot-assisted surgeries. High-volume centres like Xiamen Humanity Hospital use the Da Vinci Surgical System for precise kidney-sparing oncology procedures.
Bookimed Expert Insight: The Da Vinci system dominates 90% of the market. However, China is rapidly adopting domestic platforms like KangDuo. Xiamen Humanity Hospital alone treats 1,000,000 patients annually. This massive patient volume means urologists there often achieve high procedure counts faster than many international counterparts.
Chinese kidney cancer diagnosis aligns with international standards by using PET/CT, MRI, and biopsy protocols. Major urban centres detect over 50% of cases incidentally during routine scans. This mirrors Western trends. Specialist facilities use intraoperative MRI and Da Vinci systems for precise diagnostic accuracy before surgery.
Bookimed Expert Insight: While many centres offer fast-track imaging, major institutions like Xiamen Humanity Hospital serve 1,000,000 patients annually. This massive case volume allows specialists to identify rare kidney tumour subtypes quickly. Patients should look for hospitals with JCI accreditation, like Fuda Cancer Hospital. This helps to confirm diagnostic reports meet global documentation standards.
Patient Consensus: Patients find diagnostic pathways in China faster than in Australia. They often receive scans and biopsy results within days. They recommend requesting full DICOM imaging files and pathology reports in English. This helps with follow-up care with specialists back home.
China hosts top-tier cancer centres specialising in kidney cancer treatment. Leading facilities include JCI-accredited Fuda Cancer Hospital and Xiamen Humanity Hospital. These institutions offer laparoscopic nephrectomy and robotic-assisted surgery. Major national centres in Beijing and Shanghai provide intensive research-based oncology care.
Bookimed Expert Insight: Patient volume often dictates surgical expertise in China. Xiamen Humanity Hospital treats 1,000,000 patients annually. This scale allows specialists like Prof. Liu Shi Xin to manage complex malignancies. Australian patients should focus on facilities with over 400 beds. This helps ensure access to lab services and PET/CT diagnostics.
Patient Consensus: Patients recommend large tertiary hospitals with dedicated urologic oncology services. They emphasise confirming English support and clear pathology documentation for follow-up care in Australia.
Kidney cancer survival in China reaches approximately 69.8% for all renal cell carcinoma cases. Success likelihood for localised tumours is high. Five-year survival rates are around 93%. Specialised centres use CyberKnife M6 and Da Vinci robotic systems for high precision.
Bookimed Expert Insight: Many centres focus on standard surgery. However, Chinese oncology groups specialise in minimally invasive alternatives for late-stage cases. Fuda Cancer Hospital has treated over 30,000 international patients using cryotherapy and NanoKnife. These options help when traditional chemotherapy or open surgery is not suitable.
Patient Consensus: Patients note that success depends heavily on stage-specific plans. Success also relies on verifying that the centre offers the full treatment pathway. This includes surgery through to long-term immunotherapy and recurrence monitoring in China.
Chinese specialists offer active surveillance for kidney tumours under 4 cm. National guidelines recommend this for elderly patients or those with health risks. Doctors use regular CT or MRI scans to monitor growth. This approach helps avoid surgery for slow-growing masses.
Bookimed Expert Insight: Chinese clinics offer treatments like CyberKnife or robotic surgery. However, our data shows a shift toward minimally invasive options. JCI-accredited Fuda Cancer Hospital provides cryosurgery if surveillance reveals growth. This allows patients to avoid radical nephrectomy while managing slow-growing tumours effectively.
Patient Consensus: Patients note that Chinese doctors often recommend surgery or ablation immediately. Most advise asking specifically for a structured monitoring plan. This should include English-language imaging reports for Australian follow-ups.
Traditional Chinese Medicine (TCM) is standard practice alongside Western kidney cancer treatments in China. Over 80% of cancer patients use this integrated approach. TCM rarely replaces surgery or immunotherapy. Instead, it supports recovery and helps manage side effects in major oncology centres.
Bookimed Expert Insight: Many Australian patients associate Chinese hospitals only with herbs. However, centres like Jinshazhou Hospital of Guangzhou University of Chinese Medicine are high-tech hubs. They offer CyberKnife M6 radiosurgery alongside traditional supportive care. Patients can access A$11,200 packages that include consultations with radiation oncology experts who understand integrated medicine.
Patient Consensus: Patients note TCM in China works well for improving appetite and sleep during recovery. They emphasise that core treatment remains surgery or immunotherapy. Herbs serve as a quality-of-life boost.